HRMY

Harmony Biosciences Holdings Inc

Add to Watchlist

Advanced Chart

34.050

-0.040(-0.120%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

34.500

Open

34.000

VWAP

34.18

Vol

527.95K

Mkt Cap

1.96B

Low

33.700

Amount

18.05M

EV/EBITDA(TTM)

6.88

Total Shares

56.79M

1.62B

EV/OCF(TTM)

7.29

P/S(TTM)

2.66

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action (MOA) designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. Its narcolepsy treatment works primarily through histamine, a wake-promoting neurotransmitter. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

204.50M

+18.33%

217.98M

+17.17%

234.86M

+16.69%

Estimates Revision

The market is revising Downward the revenue expectations for Harmony Biosciences Holdings, Inc. (HRMY) for FY2025, with the revenue forecasts being adjusted by -0.26% over the past three months. During the same period, the stock price has changed by -9.78%.

Revenue Estimates for FY2025

Revise Downward

-0.26%

In Past 3 Month

Stock Price

Go Down

-9.78%

In Past 3 Month

8 Analyst Rating

55.24% Upside

Wall Street analysts forecast HRMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HRMY is 52.86 USD with a low forecast of 32.00 USD and a high forecast of 70.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

0 Hold

1 Sell

Strong Buy

55.24% Upside

Current: 34.050

Low

32.00

Averages

52.86

High

70.00

55.24% Upside

Current: 34.050

Low

32.00

Averages

52.86

High

70.00

UBS

Ashwani Verma

Strong Buy

Maintains

$55 → $48

2025-04-28

Reason

UBS

Ashwani Verma

Price Target

$55 → $48

2025-04-28

Maintains

Strong Buy

Reason

UBS lowered the firm's price target on Harmony Biosciences to $48 from $55 and keeps a Buy rating on the shares. Harmony reported Q1 in-line with consensus estimates, but notes a competitor's Q2 update on Fragile X Syndrome, the analyst tells investors in a research note.

Needham

Ami Fadia

Strong Buy

Reiterates

$50

2025-04-10

Reason

Needham

Ami Fadia

Price Target

$50

2025-04-10

Reiterates

Strong Buy

Reason

Needham

Ami Fadia

Strong Buy

Reiterates

$50

2025-04-08

Reason

Needham

Ami Fadia

Price Target

$50

2025-04-08

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$70

2025-04-08

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$70

2025-04-08

Reiterates

Strong Buy

Reason

Mizuho

Graig Suvannavejh

Buy

Maintains

$42 → $44

2025-03-18

Reason

Mizuho

Graig Suvannavejh

Price Target

$42 → $44

2025-03-18

Maintains

Buy

Reason

Mizuho raised the firm's price target on Harmony Biosciences to $44 from $42 and keeps an Outperform rating on the shares. The firm updated the company's model post the Q4 report. Harmony's lead asset Wakix making steady progress towards becoming a blockbuster product. the analyst tells investors in a research note.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Maintains

$75 → $70

2025-02-27

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$75 → $70

2025-02-27

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Harmony Biosciences Holdings Inc (HRMY.O) is 10.31, compared to its 5-year average forward P/E of 24.20. For a more detailed relative valuation and DCF analysis to assess Harmony Biosciences Holdings Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

24.20

Current PE

10.31

Overvalued PE

47.87

Undervalued PE

0.53

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

12.67

Current EV/EBITDA

5.61

Overvalued EV/EBITDA

20.80

Undervalued EV/EBITDA

4.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

4.62

Current PS

2.23

Overvalued PS

6.81

Undervalued PS

2.42

Financials

Annual

Quarterly

FY2025Q1

YoY :

+19.48%

184.73M

Total Revenue

FY2025Q1

YoY :

+8.09%

56.25M

Operating Profit

FY2025Q1

YoY :

+18.85%

45.56M

Net Income after Tax

FY2025Q1

YoY :

+16.42%

0.78

EPS - Diluted

FY2025Q1

YoY :

+8.75%

33.86M

Free Cash Flow

FY2025Q1

YoY :

+0.56%

82.68

Gross Profit Margin - %

FY2025Q1

YoY :

-11.63%

29.72

FCF Margin - %

FY2025Q1

YoY :

-0.52%

24.66

Net Margin - %

FY2025Q1

YoY :

-11.54%

20.62

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

386.5K

USD

3-6

Months

4.2M

USD

6-9

Months

141.7M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 18208.08% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.4M

Volume

Months

6-9

0.0

Volume

Months

0-12

7.9K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

386.5K

USD

3-6

Months

4.2M

USD

6-9

Months

141.7M

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

HRMY News & Events

Events Timeline

2025-05-06 (ET)

2025-05-06

07:56:22

Harmony Biosciences backs FY25 revenue view $820M-$860M, consensus $840.4M

2025-05-06

07:55:15

Harmony Biosciences reports Q1 EPS $1.03, consensus 91c

2025-03-24 (ET)

2025-03-24

08:23:32

Harmony Biosciences CCO Jeffrey Dierks steps down, Adam Zaeske succeedsTakeda

News

9.5

05-06NASDAQ.COM

Harmony Biosciences Holdings, Inc Q1 Profit Increases, Beats Estimates

9.5

05-06Investing.com

Harmony Biosciences stock surges 5% on strong Q1 earnings beat By Investing.com

9.5

05-06Newsfilter

Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance